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ABSTRACT The human immunodeficiency virus 1 (HIV-
1) long terminal repeat (LTR) sequences were inserted into
adenovirus in place ofthe El region. The HIV-l LTR contained
in this recombinant adenovirus responds to trans-activation by
tatll in a HeLa cell line constitutively expressing that HIV-i
gene product. In addition, the HIV-i LTR is activated by the
adenovirus ElA 13S, but not 12S or 9S, gene product when it
is supplied in trans by a coinfecting wild-type adenovirus. The
Rous sarcoma virus LTR, in a similar recombinant adenovirus,
is insensitive to tatI but is also trans-activated by the ElA 13S
protein. The action of the 13S ElA and WtaIl proteins are
additive for the HIV-1 LTR in the context of adenovirus and
they appear to act at the transcriptional level. As in HeLa cells,
the adenovirus-borne HIV-l LTR is inactive in the absence of
a trans-activator in H9 and Jurkat cells, two human leukemic
T-cell lines. This suggests that recombinant adenoviruses have
diagnostic potential for the detection of trans-activators of the
HIV-l LTR that are present in circulating human lymphocytes.
Transcription of human immunodeficiency virus 1 (HIV-1),
the causative agent of acquired immune deficiency syndrome
(AIDS) (1, 2), is directed by the HIV-1 long terminal repeat
(LTR) sequences. The HIV-1 LTR is composed of several
regulatory elements: a negative regulatory element (located
between nucleotides -340 and -185, relative to the cap
site), a core enhancer (-105 to - 80), three SP1 binding sites
(- 76 to - 48), a "TATA box" (- 26 to - 22), and an element
termed TAR (-17 to + 54) (3-8). The TAR element confers
responsiveness to tatIII, a HIV-1-encoded trans-acting pro-
tein. The mechanism of action of tatIlf is unclear; experi-
ments involving transfection of plasmid DNAs have sug-
gested transcriptional regulation (7, 9, 10), posttranscrip-
tional regulation (11), or a combination of the two (12-15).
The course of AIDS, from initial infection with HIV-1 to
manifestation of clinical symptoms, may be influenced by
superinfection with other viruses capable of activating latent
HIV-1. Several DNA viruses, most notably herpes simplex
virus 1, have been shown to stimulate HIV-1 LTR-directed
gene expression (16-18). The herpes gene products involved
in this trans-activation have been identified as ICPO and ICP4
(19, 20).
To study regulation of HIV-1 LTR-directed gene expres-
sion, we have inserted the HIV-1 LTR, fused to the chlor-
amphenicol acetyltransferase (CAT) gene, into adenovirus
(Ad) in place of the El region. This recombinant Ad,
HIV-lCAT-Ad, contains nucleotides -453 to + 80 from the
HIV-1 LTR. We also constructed a similar recombinant
adenovirus, RSVCAT-Ad, containing the Rous sarcoma
virus (RSV) LTR fused to the CAT gene. These two viruses
allow efficient introduction of the retroviral promoters into
cells containing various trans-acting control factors.
Transcription of wild-type Ad is under strict temporal
regulation during the infectious cycle. The EIA gene is the
first transcription unit expressed after infection and pro-
duces, by differential splicing, two major mRNAs whose
sizes are 12S and 13S. They encode polypeptides that differ
only by an additional internal 46 amino acids contained in the
larger protein (21-24). Transcriptional activation of all other
early Ad promoters is due primarily to the action of the 13S
ElA protein (25). The 13S protein also activates some
resident cellular promoters, notably the major heat shock
protein hsp 70 and 3-tubulin genes, as well as a wide variety
of both RNA polymerase II and polymerase III promoters
introduced into cells by transfection of plasmid DNAs or by
infection with recombinant Ad (reviewed in ref. 26). The ElA
proteins, particularly the 12S protein, are also able to repress
enhancer-mediated expression of some viral and cellular
genes (27, 28).
The recombinant viruses HIV-lCAT-Ad and RSVCAT-Ad
do not contain the Ad El region and, therefore, do not
produce any of the multiple protein products of the EIA and
EJB genes, including the 13S ElA protein. Consequently,
expression of Ad genes is extremely inefficient in HIV-
lCAT-Ad and RSVCAT-Ad infections. We have found that
low levels of CAT activity are expressed in HeLa cells
infected with HIV-lCAT-Ad. In contrast, several hundred-
fold higher levels of CAT expression occur after infection in
a HeLa cell line, called HeLa/tatIII (11), which constitu-
tively expresses the tatIII protein. RSVCAT-Ad expresses
equivalent levels of CAT activity in HeLa and HeLa/tatIII
cells. Thus, the HIV-1 LTR inserted in Ad responds specif-
ically to trans-activation by tatIII. This trans-activation was
investigated in detail in a separate report, (29) and was found
to occur largely, if not entirely, by a transcriptional control
mechanism. We present here further analysis of the trans-
activation of the HIV-1 LTR contained in Ad. We show that
the Ad 13S ElA gene product can activate the HIV-1 LTR,
and we extend our studies to human T cells.
MATERIALS AND METHODS
Cell Lines. HeLa and HeLa/tatIII cells (11), obtained from
C. Rosen and W. Haseltine (Harvard Medical School), were
grown as monolayer cultures in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10o fetal calf serum,
streptomycin (100 ,ug/ml), and penicillin (100 ug/ml). 293
cells (30) were grown as monolayer cultures in DMEM
supplemented with 10% calf serum, streptomycin, and pen-
Abbreviations: HIV, human immunodeficiency virus; LTR, long
terminal repeat; CAT, chloramphenicol acetyltransferase; RSV,
Rous sarcoma virus; Ad, adenovirus(es); moi, multiplicity of infec-
tion; pfu, plaque-forming unit(s); araC, cytosine arabinonucleoside.
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icillin. H9 and Jurkat cells, generously provided by R. Franza
(Cold Spring Harbor Laboratory), were grown in RPMI
medium with 20% fetal calf serum.
Construction of Recombinant Ad. To construct RSVCAT-
Ad, the Nde I/BamHI fragment, containing the RSVCAT
sequences, was removed from plasmid pRSVCAT (31) and
inserted into Ad by in vivo recombination in 293 cells by the
method of Gluzman et al. (32). HIV-lCAT-Ad was con-
structed identically using the Xho I/BamHI fragment from
pU3RIII (33). Recombinant viruses were propagated and
titered in 293 cells. Their genome structures are shown in Fig.
1.
Conditions of Infection and CAT assays. Infections in 293
cells were carried out at a multiplicity of infection (moi) of 10
plaque forming units (pfu) per cell. Infections and coinfec-
tions in HeLa, HeLa/tatIII, H9, and Jurkat cells were carried
out at a moi of 50 pfu per cell for each virus. To inhibit DNA
synthesis, some infections were done in the presence of
cystosine arabinoside (araC) (20 tug/ml), added 4 hr postin-
fection; at 12-hr intervals thereafter, the medium was re-
moved and replaced with fresh medium with or without the
drug. CAT assays were performed by the standard procedure
(31). After thin-layer chromatography, CAT assays were
quantitated with an Ambis Beta Scan System (Automated
Microbiology Systems, San Diego, CA). CAT activity is
presented as relative units, with 1 unit defined as 1%
conversion of chloramphenicol substrate to its acetylated
forms by an extract from 5 x 105 cells during a 60-min
incubation. Extracts with high CAT activity were diluted
and/or incubated for short periods so that <50% of the
chloramphenicol substrate was acetylated in the assay. All
experiments were repeated a number of times; the data
presented are from a single experiment.
Plasmid Transfections. HeLa cells were transfected by the
calcium phosphate precipitation method. Cell extracts were
prepared 48 hr after transfection, and assays were performed
as described above. Units of activity in plasmid transfections
are also as defined above.
RESULTS
Expression of CAT Activity from Recombinant Viruses in
293 Cells. The HIV-1CAT-Ad and RSVCAT-Ad viruses
contain the respective retroviral LTR, fused to the CAT
gene, inserted in place of the adenovirus El region (Fig. 1).
These viruses are propagated in human 293 cells, which
supply the El gene products in trans. To monitor CAT
expression by HIV-1CAT-Ad and RSVCAT-Ad in 293 cells,
cells were infected with each recombinant Ad, and CAT
expression was measured (Fig. 2). Only low levels of CAT
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FIG. 2. Expression of CAT activity in 293 cells. Cells were
infected at a moi of 10 pfu per cell with RSVCAT-Ad (solid line) or
HIV-1CAT-Ad (dashed line), and cell extracts were prepared and
assayed for CAT activity at the indicated time postinfection.
activity (<10 units) were expressed by both viruses up to 8
hr postinfection. However, from 12 to 36 hr postinfection,
CAT activity accumulated exponentially for both viruses, to
a level of 150,000 units for RSVCAT-Ad and 16,000 units for
HIV-1CAT-Ad. When a higher moi was used for RSVCAT-
Ad (moi, 100), CAT expression was 14, 5, and 10 units of
activity at 2, 4, and 8 hr postinfection, respectively, and it
increased to 2000 units at 12 hr postinfection and to 41,000
units at 24 hr postinfection. Similarly, when a higher moi was
used for HIV-1CAT (moi, 1000), CAT expression was <10
units of activity through 8 hr postinfection and increased
exponentially thereafter. Both recombinant Ad expressed
much higher levels of CAT activity at late times after
infection of 293 cells than at comparable times after infection
of HeLa cells (see below). This may, in part, reflect the fact
that Ad infection proceeds more rapidly in 293 cells; higher
levels of expression in HeLa cells might have been observed
if later time points had been analyzed.
Since these recombinant Ad replicate in 293 cells, CAT
expression could be affected by increased template concen-
trations. To monitor effects of DNA replication, infections
with HIV-1CAT-Ad were also carried out in the presence of
araC to prevent viral DNA replication. High levels of CAT
activity (>10,000 units) were still observed when DNA
replication was blocked but were slightly reduced relative to
levels seen in the absence of the drug (data not shown).
Control experiments in HeLa cells show that araC does not
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FIG. 1. Structure of recombinant Ad. Shown
70-80so loo j are HIV-1CAT-Ad and RSVCAT-Ad. These70 80 90 100 mop units recombinant Ad contain a deletion of Ad se-
quences from 1.4 to 9.1 map units of wild-type
AdS (Pvu II/Bgl II fragment, leaving 453 nucle-
otides of Ad left-flanking sequences; see ref. 32),
comprising all of the coding region for the EIA
genes and all but the last 60 amino acids of the
EIB genes. The site of initiation and direction of
transcription from the HIV-1 and RSV LTRs are
indicated by arrows. Also shown are the RSV and
0 mopJ HIV-1 LTRs (open box), CAT coding sequence
7080 90 100 map units (hatched box), and simian virus 40 (SV40) polya-
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inhibit CAT expression (see below). This indicates that
template concentration does affect CAT expression from the
recombinant Ad. Nevertheless, the high level of expression
of HIV-1CAT-Ad in the absence of tatIIl suggests that 293
cells contain an activator of the HIV-1 LTR.
Expression of CAT Activity in HeLa and HeLa/tatll Cells
Coinfected with Recombinant Ad and Wild-Type Ad. To
explore interactions between Ad gene product(s) and the
HIV-1 LTR, coinfection experiments were performed in
HeLa and HeLa/tatIII cells with wild-type Ad and HIV-
iCAT-Ad and RSVCAT-Ad. Wild-type Ad supplies the EIA
and EIB gene products in trans, allowing expression of Ad
genes and replication of HIV-lCAT-Ad and RSVCAT-Ad in
the coinfection. To monitor effects of viral DNA replication
during the coinfection, infections were carried out in the
presence or absence of araC (Tables 1 and 2). Little CAT
expression was detected after HIV-lCAT-Ad infection of
HeLa cells, and the presence of araC during single infection
did not affect CAT expression (Table 1). In contrast, several
hundred units ofCAT activity were detected in HeLa/tatIII
cells after infection with HIV-lCAT-Ad. Thus, the HIV-1
LTR contained in an Ad vector responds to trans-activation
by tatIII.
When wild-type Ad was coinfected with HIV-lCAT-Ad in
HeLa cells, CAT expression was detected, indicating acti-
vation of the HIV-1 LTR (Table 1). This activation did not
require DNA replication, as it occurred in coinfection in the
presence of araC, which prevents viral DNA replication and
the expression of late viral gene products. When HeLa cells
were coinfected with HIV-lCAT-Ad and Ad mutant d1312,
deleted for the El region, no trans-activation of the HIV-1
LTR was seen (M. Laspia and A.P.R., unpublished results).
It can be concluded that expression of an Ad early gene
product acts to trans-activate the HIV-1 LTR. In coinfection
of HeLa/tatIII cells, CAT activity was increased -10-fold,
indicating "super"-trans-activation of the HIV-1 LTR. This
activation also did not require DNA synthesis. The mecha-
nisms of trans-activation by tatlIl and coinfection by Ad
were found to involve transcriptional regulation (29).
The RSV LTR is active during RSVCAT-Ad infection in
both HeLa and HeLa/tatIII cells (Table 2), demonstrating
the specificity of trans-activation by tatIlI for HIV-lCAT-
Ad. In the experiment shown in Table 2, CAT activity at 36
hr postinfection of RSVCAT-Ad alone in HeLa/tatIII cells
was 1/10th that in HeLa cells. However, this low level in
HeLa/tatIII cells was not reproducible, as in four indepen-
dent experiments there was a negligible difference in expres-
sion between the two cell lines. Coinfection with wild-type
Ad stimulated expression of the RSV LTR, "100-fold at 36
hr postinfection, in both cell lines. As with HIV-lCAT-Ad,
Table 1. HIV-1CAT-Ad coinfections in the presence of araC
Time Relative CAT activity
post- HIV-1- HIV-1- HIV-1CAT-
infection, HIV-1- CAT-Ad CAT-Ad Ad + wt
hr CAT-Ad + araC + wt Ad2 Ad2 + araC
HeLa cells
12 <1 <1 <1 <1
24 <1 <1 7 5
36 <1 <1 12 96
HeLa/tatIfI cells
12 29 44 <1 41
24 67 90 3360 720
36 202 341 2430 4860
Cells were infected as indicated. All viruses were used at a moi of
Table 2. RSVCAT-Ad coinfections in the presence of araC
Time Relative CAT activity
post- RSVCAT- RSVCAT-
infection, RSVCAT- RSVCAT- Ad + wt Ad + wt
hr Ad Ad + araC Ad2 Ad2 + araC
HeLa cells
12 2 4 1,640 136
24 11 14 6,900 3,030
36 264 336 21,600 27,900
HeLa/tatIII cells
12 3 2 840 80
24 9 9 15,300 1,660
36 12 19 17,100 4,500
Cells were infected as indicated. All viruses were used at a moi of
50 pfu per cell. Extracts were prepared at 12, 24, and 36 hr
postinfection and assayed for CAT activity. After thin-layer chro-
matography, relative CAT activity was quantitated with an Ambis
Beta Scan System. wt, Wild type.
this activation did not require viral DNA synthesis. These
data show that expression of an Ad gene product acts to
trans-activate these retroviral LTRs contained in vectors.
AraC generally stimulated CAT expression at late times (36
hr postinfection) for HIV-1CAT-Ad and RSVCAT-Ad (Ta-
bles 1 and 2). This may be due to increased levels ofAd EMA
proteins in cells treated with the drug (34) and could more
than compensate for reduced template levels.
Trans-Activation of the HIV-1 LTR Requires Expression of
the 13S ElA Protein. Coinfections, in the presence of araC to
prevent DNA replication, were carried out with HIV-1CAT-
Ad and Adenovirus mutants (35) capable of expressing only
individual 13S, 12S, or 9S EMA proteins (36) (Table 3).
Clearly, expression of the 13S protein is required for trans-
activation in HeLa cells and augments trans-activation in
HeLa/tatIII cells. Neither the 12S nor the 9S protein is
sufficient for trans-activation.
In HeLa cells coinfected with this 13S virus, CAT expres-
sion was generally stimulated to 10-fold higher levels than
that obtained by coinfection with wild-type virus. This
difference could be attributed to repression by the 12S
protein produced by wild-type virus but absent in the 13S
virus. The difference was much less (a factor of <2) in
HeLa/tatIII cells where the activity of the tatIII protein
might obscure repression by the 12S protein.
We also used cotransfection ofplasmid DNAs to determine
whether the HIV-1 LTR responded to trans-activation by a
plasmid-borne EMA 13S protein. A plasmid expressing CAT
under control of the HIV-1 LTR was cotransfected into HeLa
cells with plasmids expressing tatIII, EMA 13S, or EMA 12S
Table 3. HIV-1CAT-Ad coinfections
Time Relative CAT activity
post- HIV-1- HIV-1- HIV-1- HIV-1-
infection, HIV-1- CAT-Ad CAT-Ad CAT-Ad CAT-Ad
hr CAT-Ad + wt Ad2 + 13S Ad + 12S Ad + 9S Ad
HeLa cells
12 <1 <1 <1 <1 <1
24 <1 15 33 1 1
36 2 18 194 2 5
HeLa/tatIII cells
12 8 16 10 5 9
24 36 510 750 23 37
36 525 2160 3030 114 129
Cells were infected as indicated. All viruses were used at a moi of
50 pfu per cell. Extracts were prepared at 12, 24, and 36 hr
postinfection and assayed for CAT activity. After thin-layer chro-
matography, relative CAT activity was quantitated with an Ambis
Beta Scan System.
50 pfu per cell, and araC was used at 20 jug/ml. Extracts were
prepared at 12, 24, and 36 hr postinfection and assayed for CAT
activity. After thin-layer chromatography, relative CAT activity was
quantitated with an Ambis Beta Scan System. wt, Wild type.
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proteins (Table 4). As in coinfection experiments, cotrans-
fection of plasmid DNAs showed that the HIV-1 LTR was
trans-activated by the ElA 13S, but not 12S, protein. The
magnitude of trans-activation by the 13S ElA protein was
considerably higher in coinfection of virus than in cotrans-
fection of plasmids (100-fold vs. 4-fold; Table 3), perhaps
reflecting a more efficient delivery of both the HIV-1 LTR
and 13S EIA gene into cells.
Trans-Activation May Require a cis-Modification of the
HIV-1 LTR. The kinetics of CAT expression in coinfections
of HeLa cells with HIV-1CAT-Ad and wild-type or 13S Ad,
or in single infection of 293 cells, are noteworthy. There is
little expression up to 12 hr postinfection, and then it
increases exponentially to 36 hr postinfection (Tables 1-3;
Fig. 2). Because this activation occurs in the presence of
araC, we infer that expression of an early Ad gene product is
involved in transcriptional activation of the HIV-1 LTR,
either directly or indirectly through a second viral or cellular
trans-acting factor, and that it may require 12 hr for the
appearance or activation of this factor(s).
We carried out a superinfection experiment, similar to
those of Thomas and Mathews (37) and Gaynor and Berk
(38), to address this possibility. The superinfection was
carried out in the presence of araC to prevent possible
complications due to viral DNA synthesis. HeLa and
HeLa/tatIII cells were first infected with wild-type Ad for 14
hr and then superinfected with HIV-1CAT-Ad. CAT activity
was assayed in cell extracts prepared throughout superinfec-
tion (Table 5). If the lag in expression of the HIV-1 LTR in
coinfection is due to the time required for the appearance of
an adenovirus-induced transcription factor, then in the su-
perinfection experiment the LTR should be expressed with a
greatly decreased lag. It is clear from Table 5 that expression
of the HIV-1 LTR still undergoes a long lag period, although
preinfected with wild-type Ad for 14 hr. We conclude that the
12-hr lag before expression cannot be simply explained by the
time required for the build up of a trans-acting factor.
Although CAT mRNA levels and transcription rates of the
HIV-1 LTR promoted CAT gene were not measured directly
in the superinfection experiment shown in Table 5, CAT
assays appear to be a valid measure of relative transcription
rates in the Ad vector system (29). We feel that the most likely
explanation for the result shown in Table 5 is that the HIV-1
LTR must undergo some cis modification-for instance,
assembly of a transcription complex and this requires -12
hr-before it can be expressed from the Ad chromosome.
Similar data and conclusions were reached by Gaynor and
Berk in a study, using superinfection experiments, that
analyzed transcription of Ad early region 3 (38).
Expression of HIV-lCAT-Ad and RSVCAT-Ad in Human
T-Cell Lines. Expression ofHIV-1CAT-Ad and RSVCAT-Ad
was monitored in two human T-cell leukemic lines, H9 and
Jurkat. After single or coinfection of both cell lines, extracts
were prepared 48 hr postinfection and assayed for CAT
activity (Fig. 3). HIV-1CAT-Ad expressed no detectable
CAT activity in single infection in either H9 or Jurkat cells,
a result similar to that obtained in HeLa cells. However,
coinfection with wild-type Ad activated the HIV-1 LTR,
Table 4. Plasmid cotransfections in HeLa cells
Relative CAT activity
HIV LTR tatIff ElA 13S ElA 12S
4 >70 16 2
HeLa cells were transfected with a plasmid expressing CAT under
control of the HIV-1 LTR (pU3RIII; ref. 37) along with plasmids
expressing tatIfi under control of the HIV-1 LTR (ref. 37), ElA 13S
protein, or ElA 12S protein (both under control of the metallothio-
nein-1 promoter; ref. 36). Cell extracts were prepared 48 hr after
transfections and assayed for CAT activity.
Table 5. HIV-ICAT-Ad superinfection
Relative CAT activity
Time Coinfection Preinfection
postinfection, with wt with wt
hr HIV-1CAT-Ad Ad2 Ad2
HeLa cells
2 <1 <1 <1
4 <1 <1 <1
7 <1 <1 <1
12 <1 <1 <1
27 2 22 300
31 3 810 610
HeLa/tatlIl cells
2 <1 <1 <1
4 <1 <1 <1
7 <1 <1 <1
12 42 3 7
27 466 1260 3930
31 260 1980 4950
Cells were infected with HIV-1CAT-Ad alone, coinfected with
HIV-1CAT-Ad and wild-type (wt) Ad2, or preinfected with wt Ad2
for 14 hr prior to superinfection with HIV-1CAT-Ad. Infections were
carried out in the presence ofaraC, and all viruses were used at a moi
of 50 pfu per cell. Cell extracts were prepared 2, 4, 7, 12, 27, and 31
hr postinfection, and relative CAT activity was determined as
described in Tables 1-4.
again as in HeLa cells. RSVCAT-Ad expressed CAT activity
when infected alone in both H9 and Jurkat cells, as in HeLa
and HeLa/tatIII cells, and coinfection with wild-type Ad also
stimulated the RSV LTR in H9 and Jurkat cells. Thus, it
seems likely that in lymphoid cells trans-activators that are
not normally present are required for HIV-1, but not for RSV
LTR expression.
DISCUSSION
We have used a recombinant Ad containing the HIV-1 LTR
to study regulation of HIV-1 promoter activity by homolo-
gous and heterologous trans-activators-namely, the HIV-1
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FIG. 3. Expression of CAT activity in human T-cell lines. H9
and Jurkat cells were infected with HIV-1CAT-Ad (lanes 1 and 5),
HIV-1CAT-Ad and wild-type Ad (ad2) (lanes 2 and 6), RSVCAT-Ad
(lanes 3 and 7), or RSVCAT-Ad and wild-type Ad (lanes 4 and 8), and
48 hr postinfection cell extracts were prepared and assayed for CAT
activity. All viruses were used at a moi of 50 pfu per cell. Levels of
CAT activity expressed were: 1, 5, 42, >90, <1, 9, 28, and >90 units
(lanes 1-8, respectively).
Biochemistry: Rice and Mathews
4204 Biochemistry: Rice and Mathews
tatIII protein and Ad ElA proteins. In this system, the HIV-1
LTR contained in Ad is trans-activated by tatIlf largely, ifnot
entirely, at the transcriptional level (29). Transcriptional
regulation of the HIV-1 LTR by tatIII has also been observed
in plasmid transfection experiments in COS cells (15) and is
reported to operate through suppression of a termination of
transcription that normally occurs -55 nucleotides 3' to the
cap site, rather than by increasing the rate of initiation of
transcription from the HIV-1 LTR (10).
The HIV-1 LTR contained in Ad is inactive in HeLa, H9,
and Jurkat cells in the absence of either the tatIII or Ad 13S
ElA proteins (Table 1; Fig. 3). In HeLa cells, these trans-
activators can act separately or additively to stimulate HIV-1
LTR-directed transcription. While the action of tatIII is
specific to the HIV-1 LTR, the 13S ElA protein also
trans-activates the RSV LTR contained in Ad. A wide variety
of both RNA polymerase II and III genes introduced into
cells as plasmid DNAs or recombinant Ad is activated by the
13S protein, but in no case is the mechanism of action of the
13S protein clear. No DNA consensus sequence involved in
13S activity has been identified, and the 13S ElA protein is
not thought to interact directly with DNA (39). Rather, the
13S protein may stimulate the activity of cellular transcrip-
tion factors, and the precise nature of the interaction between
EMA and such factors may be promoter specific (40, 41).
When the 13S protein, supplied by a coinfecting wild-type
Ad, activates the HIV-1 LTR contained in the recombinant
Ad, there is an::12-hr lag period prior to expression. This lag
cannot be reduced by 14-hr preinfection with wild-type virus
prior to infection with the recombinant Ad (Table 5). The lag
in expression is also observed in 293 cells, which constitu-
tively express the 13S protein. These results support the
model that the 13S protein acts to facilitate a cis modification
of the HIV-1 LTR, such as assembly of a transcription
complex, prior to transcription. Interestingly, the HIV-1
LTR contained in Ad, when trans-activated by tatIII, also
undergoes a similar 12-hr lag prior to expression (Tables 1 and
3).
Expression of the 13S EMA protein is required for Ad-
mediated trans-activation of the HIV-1 and RSV LTRs
contained in Ad; the 12S and 9S proteins do not suffice. This
activation does not involve expression of Ad late genes
(Tables 1-3), but since expression of the 13S protein activates
all the other early Ad promoters, additional early gene
products may be involved. We have ruled out a role for the
Ad EIB genes, as coinfection of HIV-1CAT-Ad with Ad
mutants unable to express E1B proteins in both HeLa and
HeLa/tatIII cells resulted in trans-activation equivalent to
that seen with wild-type Ad (A.B.R. and E. White, unpub-
lished results). We have also ruled out a role for the E3 gene,
as coinfection of HIV-1CAT-Ad with Ad d1309, both deleted
for E3, resulted in trans-activation (M. Laspia and A.P.R.,
unpublished results). We cannot at present rule out involve-
ments of the E2 and E4 genes in coinfection experiments,
although plasmid transfection experiments show they are not
necessary for trans-activation (Table 4; ref. 19). Because
HIV-1CAT-Ad and RSVCAT-Ad encode the E2 and E4
genes, it will be necessary to construct additional recombi-
nant Ad to resolve this issue.
Because the expression of CAT activity from HIV-1CAT-
Ad is dependent on the presence of a trans-activator in the
infected cell, recombinant Ad such as those described here
have diagnostic potential.
Note Added in Proof. Nabel et al. (42) have also shown that the Ad
135 EMA protein trans-activates the HIV-1 LTR.
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